eligibility_summary
Adults (≥18) with initial or first relapsed indolent NHL (FL grade 1–3a, MZL, or MCL) confirmed by histology, who consent and are considered likely to benefit from immunochemotherapy. Exclude those with contraindications to study drugs, pregnant/lactating, or of childbearing potential not using contraception during treatment and 30 days after, and anyone deemed unsuitable by investigators.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-center observational study in China evaluating real-world immunochemotherapy for small B‑cell iNHL (FL 1–3a, MZL, MCL). Interventions are standard regimens chosen by investigators, e.g., R‑CHOP, BR, R‑CVP. Drug types and mechanisms: rituximab (anti‑CD20 monoclonal antibody) depletes malignant B cells via ADCC, complement activation, and apoptosis, bendamustine (alkylator) and cyclophosphamide (alkylator) cause DNA crosslinking/strand breaks, doxorubicin (anthracycline/topoisomerase II inhibitor) induces DNA damage and ROS, vincristine (vinca alkaloid) disrupts microtubules/mitosis, prednisone (glucocorticoid) triggers lymphocyte apoptosis. Primary cellular targets/pathways: CD20+ B cells, Fcγ receptor–mediated immune effector functions, complement cascade, DNA replication/repair pathways, mitotic spindle assembly, glucocorticoid receptor signaling.